There were 1,862 press releases posted in the last 24 hours and 439,431 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image